RNA – PharmaLive

How Can We Engage Patients and Physicians in the “Next Big Thing?”

Annual Reports, Antimicrobials, April 2022, Caregivers, Coronavirus Disease (COVID-19) Pandemic, Digital therapeutics, Doctors, HCPs, Issue Archives, Marketing & Advertising, Med Ad News, Messenger RNA, Patients, Physicians, Sander Flaum Column

Looking past COVID, the medical world is in turmoil. It’s hard enough for us in manufacturing and marketing to keep up with innovative technologies. Patients and caregivers have it especially tough since they are on the brunt end of disruptive innovations. Every day, patients face a ceaseless onslaught of sort of truths, half-truths, and flat-out lies about their healthcare, and HCPs no sooner graduate from med school than they discover much of their training is obsolete. Flaum Navigators Principal Sander A. Flaum explores how we can engage patients and physicians in the “Next Big Thing.”

May 2, 2022/by Andrew Humphreys

Novartis Undertakes Transformational Makeover to Fortify International Position

Appointments, Business, Cost Savings, Eliminations, Integration, Job Cuts, New Hire, Novartis, People on the Move, Product Pipeline, R&D, Restructuring, RNA, RNA Interference (RNAi), Sandoz, Therapeutics

As Novartis explores the possible sell-off of its Sandoz business, the company is undergoing a significant transformation that it says will save about $1 billion in operations costs by 2024.

April 4, 2022/by BioSpace

U.S. FDA Approves Cabenuva for Virologically Suppressed Adolescents Living With HIV Who Are 12 Years of Age or Older and Weigh at Least 35 kg

Adolescents, Antiretroviral Therapy, Approvals, Expanded Indication, FDA, HIV-1, RNA, Therapeutics, ViiV Healthcare, Virology

The U.S. Food and Drug Administration approved ViiV Healthcare’s Cabenuva (cabotegravir, rilpivirine) for the treatment of HIV-1 in virologically suppressed adolescents (HIV-1 RNA less than 50 copies per milliliter [c/mL]) who are 12 years of age or older and weigh at least 35kg on a stable antiretroviral regimen, with no history of treatment failure, and with no known or suspected resistance to either cabotegravir or rilpivirine.

March 29, 2022/by Business Wire

Lilly Pumps $700 Million into Boston-Based RNA Therapeutics Facility

Boston, Business, Facilities/Sites/Manufacturing, Immunology, Launches, Massachusetts, R&D, RNA

Lilly is investing $700 million to build a state-of-the-art facility in the Boston Seaport, as part of plans to advance the company’s RNA-based research and development activities.

February 22, 2022/by Andrew Humphreys

Startup Remix Inks RNA Collaboration with Janssen Valued at $1 Billion

Immunology Companies, Janssen, Johnson & Johnson, Oncology, R&D, RNA

RNA-focused Remix Therapeutics agreed on a strategic small-molecule discovery and development collaboration with Janssen Pharmaceutica N.V., a division of Johnson & Johnson.

February 17, 2022/by BioSpace

Aside from vaccines, the advent of several effective COVID-19 antiviral therapies, including Pfizer’s Paxlovid, provides hope for ending the pandemic. Details about the U.S. government’s contract with Pfizer for 10 million doses of Paxlovid are emerging, with some unusual elements.

February 2, 2022/by BioSpace

Temps are falling and so is investor cash as BioSpace reviewed which biotech companies are scooping up the dollars.

January 26, 2022/by BioSpace

Yvonne Greenstreet Aims to Take Alnylam to the Top 5 by 2025

Appointments, Biotech, Business, J.P. Morgan Healthcare Conference, Market Cap, New Hire, People on the Move, R&D, RNA Interference (RNAi)

Led by new CEO Dr. Yvonne Greenstreet, Alnylam Pharmaceuticals has a stated ambition to transition the RNA interference therapeutics trailblazer to a top 5 biotech – measured by market capitalization – within the next five years.

January 21, 2022/by BioSpace

Global Roundup: UCB Snaps Up Rare Disease Company Zogenix

Acquisitions, Business, Cancer, Clinical Trials, Collaborations, Efficacy Data, EMA, Monoclonal Antibodies, Proteasome Inhibitors, R&D, Rare Diseases, RNA

Belgium’s UCB is acquiring California-based Zogenix, a company focused on rare diseases, in a deal valued up to €1.7 billion ($1.9 billion).

January 20, 2022/by BioSpace

JPM Day 2: Amgen, GSK, 2seventy Bio Prepare for Transformative 2022

Amgen, Business, Cell Therapy, Clinical Trials, Consumer Healthcare, Demergers, GlaxoSmithKline, J.P. Morgan Healthcare Conference, Partnerships, Product Pipelines, R&D, RNA

Amgen Chief Executive Officer Robert Bradway is excited about 2022. During his presentation at the J.P. Morgan Healthcare Conference, Bradway said things are lining up for long-term growth for the California-based company.

January 12, 2022/by BioSpace

How Can We Engage Patients and Physicians in the “Next Big Thing?”

Novartis Undertakes Transformational Makeover to Fortify International Position

U.S. FDA Approves Cabenuva for Virologically Suppressed Adolescents Living With HIV Who Are 12 Years of Age or Older and Weigh at Least 35 kg

Lilly Pumps $700 Million into Boston-Based RNA Therapeutics Facility

Startup Remix Inks RNA Collaboration with Janssen Valued at $1 Billion

Paxlovid Deal Details and Assessment of Pandemic Response Begins

Money on the Move: January 19 – 25

Yvonne Greenstreet Aims to Take Alnylam to the Top 5 by 2025

Global Roundup: UCB Snaps Up Rare Disease Company Zogenix

JPM Day 2: Amgen, GSK, 2seventy Bio Prepare for Transformative 2022